human
interferon
ifn
respons
key
innat
immun
mechan
fight
viru
infect
ifn
hostencod
secret
protein
induc
ifnstimul
gene
isg
antivir
properti
among
three
class
ifn
type
iii
ifn
also
call
ifn
lambda
ifnl
essenti
compon
innat
immun
respons
hepat
c
viru
hcv
particular
human
polymorph
ifnl
gene
loci
correl
hepat
c
diseas
progress
treatment
respons
date
underli
mechan
remain
mostli
elus
howev
seem
clear
viral
infect
liver
induc
ifnl
respons
ifnl
receptor
show
restrict
tissu
express
receptor
class
ifn
ifnl
treatment
reduc
side
effect
compar
classic
type
ifn
treatment
hcv
therapi
howev
ifnl
like
play
import
role
highli
effect
direct
act
antivir
daa
exist
review
current
knowledg
ifnl
gene
express
protein
properti
signal
isg
induct
implic
hcv
infect
treatment
final
discuss
lesson
learnt
hcv
ifnl
field
viru
infect
beyond
hepat
c
interferon
ifn
innat
cytokin
interfer
viru
infect
type
ifn
discov
first
type
iii
ifn
name
ifn
lambda
lambda
ifn
lambda
describ
recent
member
type
iii
ifn
ifn
lambda
discov
even
ten
year
later
four
ifnl
encod
chromosom
region
infl
share
open
read
frame
structur
famili
cytokin
compris
five
exon
four
intron
therefor
also
term
high
degre
sequenc
similar
amino
acid
conserv
close
relat
find
suggest
common
ancestor
gene
ifnl
express
consequ
frameshift
mutat
gene
product
share
sequenc
similar
three
ifnl
tabl
figur
protein
roughli
kda
size
slightli
smaller
kda
share
alpha
helic
bundl
structur
type
type
ii
ifn
famili
member
signific
differ
occur
side
chain
amino
acid
differ
receptor
bind
site
like
contribut
differ
ifnl
respons
detail
express
ifnl
gene
tightli
control
express
profil
ifnl
subtyp
ligand
tissu
specif
typic
rna
viru
infect
concomit
exposur
cell
foreign
rna
cytoplasm
endosom
compart
lead
ifnl
induct
particular
sindbi
viru
dengu
viru
vesicular
stomat
viru
encephalomyocard
viru
respiratori
syncyti
viru
influenza
viru
sendai
viru
hepat
c
viru
hcv
shown
induc
ifnl
vitro
vivo
addit
rna
virus
dna
virus
includ
cytomegaloviru
herp
simplex
viru
induc
ifnl
almost
cell
type
express
ifnl
promin
produc
b
maaawtvvlvtlvlglavagpvptsk
ptttgkgchigrfkslspqelasfkka
mkldmtgdctpvlvlmaavltvtgavpvarlhgalpdargchiaqfkslspqelqafkra
mtgdcmpvlvlmaavltvtgavpvarlrgalpdargchiaqfkslspqelqafkra
rdaleeslklknwscsspvfpgnwdlrllqvrerpvaleaelaltlkvleaa
agpal
kdaleeslllkdcrchsrlfprtwdlrqlqvrerpmaleaelaltlkvleatadtdp
kdaleeslllkdckcrsrlfprtwdlrqlqvrerpvaleaelaltlkvleatadtdp
ifnl
protein
id
exon
indic
black
white
box
sequenc
posit
helic
indic
line
sequenc
ident
amino
acid
mark
asterisk
conserv
amino
acid
colon
semiconserv
amino
acid
period
antivir
cytokin
myeloid
plasmacytoid
dendrit
cell
tissu
strong
ifnl
induct
upon
viru
infect
lung
liver
strong
contribut
airway
epitheli
cell
hepatocyt
limit
data
avail
express
kinet
ifnl
differ
cell
type
seem
howev
ifnl
express
onset
durat
differ
four
subtyp
instanc
primari
human
hepatocyt
phh
carri
singl
nucleotid
polymorph
snp
respons
express
show
earli
short
express
h
stimul
detect
h
stimul
synthet
poli
c
rna
ligand
differ
posit
neg
feedback
mechan
may
explain
vari
express
kinet
ifnl
subtyp
typic
induc
simultan
reflect
common
transcript
factor
bind
site
promot
region
activ
protein
ifn
respons
factor
nuclear
factor
kappa
beta
nfkb
thought
bind
promot
infl
gene
addit
seem
transcript
coactiv
taken
togeth
ifnl
induc
upon
sens
viru
infect
particular
lung
liver
infect
receptor
four
ifnl
compos
two
subunit
alphasubunit
encod
chromosom
betasubunit
encod
chromosom
former
specif
ifnl
receptor
ifnlr
latter
share
type
ii
cytokin
receptor
restrict
express
subunit
lead
tissu
specif
respons
ifnl
particular
tissu
high
epitheli
cell
content
like
intestin
liver
lung
express
respond
ifnl
apart
primari
human
hepatocyt
hepatocellular
carcinoma
cell
line
includ
cell
respond
ifnl
addit
full
length
secret
form
lack
exon
vi
describ
may
function
decoy
receptor
dampen
ifnl
respons
ifnl
ligandreceptor
interfac
compris
helix
loop
ab
helix
f
ifnl
ntermin
domain
well
interdomain
hing
region
ifnlr
van
der
waal
hydrophob
forc
determin
ligandreceptor
interact
amino
acid
critic
receptor
bind
differ
ifnl
subtyp
might
lead
differ
ligand
bind
affin
well
differ
stabil
ligandreceptor
complex
addit
mutat
receptor
bind
site
journal
immunolog
research
describ
gener
frameshift
mutat
best
describ
impact
genet
variant
discuss
detail
taken
togeth
four
ifnl
protein
share
cell
surfac
receptor
primarili
express
intestin
lung
liver
tissu
signal
respons
ifnl
initi
dimer
two
ifnlr
subunit
initi
bind
ifnl
induc
recruit
lead
activ
receptor
associ
kinas
janu
kinas
tyrosin
kinas
crosstyrosin
phosphoryl
ifnlr
subsequ
recruit
signal
transduc
activ
transcript
stat
receptor
platform
phosphoryl
form
heterotrim
togeth
ifn
regulatori
factor
trimer
complex
call
ifnstimul
gene
factor
transloc
nucleu
bind
ifn
regul
respons
element
isr
drive
ifnstimul
gene
isg
express
antivir
effect
ifnl
larg
share
type
ifn
howev
differ
receptor
tissu
express
kinet
stat
pathway
induct
exist
two
ifn
class
cell
ifnl
induc
slower
sustain
isg
respons
among
hundr
isg
induc
ifnl
type
ifn
myxoviru
influenza
viru
resist
oligoadenyl
synthetas
protein
kinas
r
pkr
isg
interfer
differ
stage
viral
life
cycl
review
antiinflammatori
isg
suppressor
cytokin
signal
howev
specif
induc
ifnl
type
ifn
protein
interfer
stat
signal
therefor
lead
desensit
type
ifn
ifnl
addit
induc
express
rant
fo
gene
hepatoma
cell
gene
hallmark
hcvinduc
liver
damag
interestingli
contrast
type
inf
ifnl
isg
ifn
stimul
hepatoma
cell
induc
express
although
high
sequenc
homolog
differ
antivir
activ
display
strongest
antivir
activ
challeng
experi
encephalomyocard
viru
find
line
strong
isg
induct
hepatocyt
turn
display
antivir
activ
compar
shown
report
cell
express
ifnlr
luciferas
gene
control
promot
conclus
ifnl
signal
pathway
isg
induct
set
isg
larg
overlap
induc
type
ifn
genu
hepaciviru
flavivirida
famili
hcv
envelop
viru
singlestrand
positiveorient
rna
genom
kbp
length
accord
genom
sequenc
divers
hcv
classifi
seven
genotyp
multipl
subtyp
liver
tropic
viru
enter
hepatocyt
multistep
process
involv
sever
host
cell
protein
review
eg
phdepend
fusion
viral
membran
endosom
membran
viral
genom
releas
cytoplasm
positiveorient
rna
genom
directli
translat
singl
polyprotein
cleav
viral
cellular
proteas
structur
nonstructur
ns
protein
replic
viru
assembl
occur
endoplasm
reticulum
er
associ
membran
structur
call
membran
web
mw
review
eg
hcv
assembl
matur
bud
releas
occur
close
contact
cellular
low
densiti
lipoprotein
synthesi
pathway
nascent
hcv
particl
releas
cell
via
secretori
pathway
bloodstream
directli
infect
bystand
cell
review
eg
schemat
overview
hcv
life
cycl
depict
figur
worldwid
million
peopl
repres
approxim
world
popul
chronic
infect
hcv
one
caus
agent
viral
hepat
hcv
blood
born
viru
transmiss
occur
parenter
mainli
reus
inject
materi
insuffici
steril
medic
tool
transfus
unscreen
blood
blood
product
screen
blood
product
standard
procedur
nowaday
countri
peopl
inject
drug
highest
risk
contract
hepat
c
fact
inject
drug
user
posit
hcvantibodi
natur
hcv
infect
human
chimpanze
experiment
infect
case
hcv
target
liver
particular
hepatocyt
narrow
host
rang
determin
presenc
absenc
certain
host
cell
factor
protein
critic
need
hcv
entri
like
cell
surfac
receptor
scaveng
receptor
bi
srbi
occludin
ocln
review
eg
molecul
need
viral
replic
like
microrna
express
hepatocyt
hand
protein
suppress
hcv
infect
like
absent
hepatocyt
acut
infect
mainli
asymptomat
hcv
establish
lifelong
persist
intrahepat
infect
approxim
patient
develop
chronic
hepat
c
chc
lead
progress
liver
fibrosi
eventu
cirrhosi
chc
patient
caus
liver
failur
develop
hepatocellular
carcinoma
chc
induc
cirrhosi
patient
per
year
consequ
hcv
caus
app
death
per
year
chc
classic
treat
recombin
pegifnalpha
combin
ribavirin
rbv
treatment
durat
long
week
wear
pegifnalpha
administ
time
week
sever
side
effect
occur
frequent
still
approxim
half
patient
cure
sinc
hcv
therapi
improv
drastic
sever
direct
act
antivir
target
hcv
proteas
rnapolymeras
approv
inhibitor
either
alon
combin
rbv
heal
patient
treat
direct
act
antivir
daa
effect
pegifnalpha
elimin
hcv
also
treatment
durat
shorter
minimum
week
administ
oral
advers
event
fewer
despit
advanc
drug
develop
vaccin
hcv
still
avail
detail
refer
reader
elsewher
exampl
innat
immun
respons
serv
first
line
defens
infect
pathogen
associ
molecular
pattern
pamp
recogn
extraor
intracellular
pattern
recognit
receptor
prr
trigger
signal
cascad
lead
product
cytokin
includ
interferon
innat
immun
respons
hcv
summar
figur
hcv
infect
cell
doublestrand
ds
rna
replic
intermedi
gener
recogn
pamp
cytosol
rna
sensor
retino
acidinduc
gene
rigi
melanoma
differentiationassoci
gene
belong
famili
rigi
like
receptor
rlr
sens
hcv
rigi
lead
oligomer
adaptor
protein
mitochondria
antivir
signal
mav
also
call
cardif
visa
larg
signal
complex
besid
cytosol
hcv
dsrna
also
present
extracellular
er
endosom
compart
extracellular
dsrna
mayb
releas
die
cell
taken
uninfect
neighbor
cell
class
scaveng
receptor
endocytosi
dsrna
brought
endosom
bound
tolllik
receptor
altern
might
engag
hcv
autophag
vesicl
hcv
replic
cell
display
enhanc
amount
recognit
dsrna
activ
tir
domaincontain
adapterinduc
ifn
trif
also
call
signal
mav
trif
trigger
signal
cascad
lead
activ
differ
cytosol
kinas
b
kinas
ikk
tankbind
kinas
turn
induc
activ
key
transcript
factor
nfb
upon
activ
protein
transloc
nucleu
bind
promot
element
type
type
iii
ifn
gene
inflammatori
cytokin
ifn
express
initi
bind
secret
ifn
receptor
autocrin
paracrin
manner
lead
activ
jakstat
pathway
depict
figur
ultim
trigger
express
hundr
ifnstimul
gene
isg
gener
antivir
state
limit
hcv
replic
chc
innat
immun
respons
control
hcv
replic
complet
elimin
viru
partial
due
viral
mechan
counteract
immun
respons
briefli
hcv
serin
proteas
shown
inhibit
phosphoryl
cleav
inactiv
rigi
adaptor
protein
mav
adaptor
protein
trif
interestingli
recent
discov
member
genu
hepaciviru
infect
nonhuman
mammal
carri
enzym
capabl
cleav
cognat
host
mav
also
human
mav
suggest
yet
studi
hepacivirus
antagon
human
antivir
innat
immun
respons
barrier
zoonot
transmiss
level
innat
immun
interfer
human
chronic
infect
hcv
display
increas
ifnl
express
specif
dolganiuc
et
al
show
ifnl
serum
level
higher
chc
patient
hcvneg
liver
inflamm
author
observ
elev
express
ifnlr
liver
biopsi
chc
patient
studi
liver
biopsi
infect
patient
also
help
confirm
associ
ifnl
isg
express
level
name
ifnl
express
lead
elev
isg
induct
particular
correl
activ
protein
isg
induct
discov
surprisingli
high
isg
level
neg
impact
outcom
hcv
infect
treatment
see
section
host
immun
respons
acut
hcv
infect
studi
experiment
infect
chimpanze
genet
human
mice
liver
chimpanze
strong
host
respons
detect
includ
induct
type
iii
ifn
transcript
isg
express
especi
mrna
protein
level
elev
correl
isg
express
viremia
howev
link
type
iii
ifn
express
liver
peripher
organ
infect
chimpanze
outcom
acut
infect
consist
immunocompet
transgen
mice
express
human
hcv
entri
factor
hcv
infect
result
upregul
sever
isg
consist
observ
mouseliv
deriv
cell
produc
type
iii
ifn
transfect
hcv
subgenom
rna
lead
abrog
hcv
replic
note
current
mous
model
allow
chronic
hcv
infect
sinc
ban
chimpanze
experiment
immunocompet
anim
model
studi
chc
recent
effort
establish
altern
nonhuman
primat
model
hepat
c
use
rodent
hepacivirus
surrog
infecti
agent
studi
chc
might
resolv
hurdl
futur
hepatocyt
type
iii
ifn
isg
similarli
induct
upon
hcv
infect
primari
human
fetal
liver
cell
magnitud
induct
differ
donor
donor
correl
viru
replic
studi
differ
aspect
hcv
life
cycl
hepatoma
cell
line
frequent
use
similar
hcv
infect
primari
cell
also
hepatoma
cell
line
induc
ifnl
transcript
upon
infect
interestingli
israelow
et
al
show
ifnl
induct
attenu
hcv
replic
ifnl
respons
cell
stabli
replic
hcv
subgenom
blunt
probabl
due
mav
cleavag
hcv
regard
hong
et
al
found
endogen
transcript
poorli
induc
upon
stimul
hcv
differ
hepatoma
cell
line
phh
also
reduc
level
secret
compar
detect
upon
hcv
infect
partial
retent
cytoplasm
observ
cell
phh
differ
studi
might
explain
observ
clear
correl
ifnl
induct
hcv
attenu
observ
hepatoma
cell
line
reflect
observ
chc
patient
sever
reason
first
complex
liver
contribut
kupffer
cell
liver
sinusoid
endotheli
cell
stellat
cell
infiltr
addit
immun
cell
review
obvious
mimick
simpl
cell
cultur
model
second
transform
cell
line
necessarili
resembl
primari
hepatocyt
fact
hepatoma
cell
line
infect
hcv
mount
strong
innat
immun
respons
nevertheless
hepatoma
cell
line
regularli
use
studi
effect
exogen
ad
ifnl
hcv
infect
typic
express
compon
ifnlr
pathway
ifnl
stimul
reduc
level
subgenom
full
length
genom
hcv
rna
cell
dose
dependentmann
result
confirm
sever
hepatoma
cell
line
includ
deriv
lunet
cell
express
firefli
luciferas
gene
cell
express
hepatoma
cell
line
phh
also
use
studi
ifnl
subtyp
differ
abil
limit
viral
infect
induc
set
isg
phh
two
subtyp
antivir
activ
hcv
overexpress
setup
hepatoma
cell
summari
express
specif
ifnl
subtyp
induc
phh
hepatoma
cell
line
upon
infect
hcv
result
limit
viru
product
howev
major
hepatoma
cell
line
elicit
strong
immun
respons
ifnl
express
novel
model
system
includ
stem
cell
deriv
hepatocyt
tissu
engin
system
might
futur
allow
faith
mimic
host
respons
hepatotrop
viru
infect
establish
pegifnalpha
rbv
standard
care
treatment
hepat
c
becam
clear
patient
african
ancestri
significantli
lower
cure
rate
european
ancestri
ifnalpharbv
treatment
two
genomewid
associ
studi
discov
ifnl
gene
polymorph
underli
genet
basi
differ
ifnalpharbv
treatment
respons
well
differ
spontan
clearanc
rate
work
spur
investig
ifnl
gene
snp
role
hcv
infect
treatment
three
major
snp
near
gene
correl
hcv
treatment
respons
high
linkag
disequilibrium
polymorph
ct
locat
kb
upstream
gene
tg
locat
gene
origin
name
creat
frameshift
upstream
gene
lead
gener
new
gene
product
three
snp
first
allel
variant
associ
higher
probabl
sustain
virolog
respons
ifnalpharbv
treatment
locat
three
snp
chromosom
schemat
depict
figur
treatment
respons
depend
ifnl
polymorph
demonstr
sever
hcv
genotyp
chronic
patient
genotyp
ifnl
snp
strongest
predictor
respons
known
date
addit
three
describ
snp
six
addit
snp
ifnl
locu
describ
strongli
associ
sustain
virolog
respons
ifnalpharbv
treatment
ifnl
snp
mechanist
influenc
treatment
outcom
mostli
unclear
initi
suspect
snp
alter
transcript
regul
locat
upstream
code
sequenc
could
influenc
transcript
factor
bind
dna
methyl
howev
studi
detect
correl
protect
ifnl
snp
higher
ifnl
express
level
fail
see
detail
descript
mechanist
snp
suggest
influenc
mrna
stabil
favor
allel
stabl
snp
function
impact
best
describ
variant
result
express
pseudogen
tt
carrier
express
associ
increas
isg
level
turn
worsen
treatment
outcom
might
seem
counterintuit
line
observ
patient
increas
pretreat
isg
level
liver
respond
poorli
ifnalpharbv
therapi
thu
seem
least
case
advers
effect
hepat
c
desensit
liver
ifnalpharbv
treatment
confirm
independ
studi
code
snp
result
less
activ
variant
consequ
improv
treatment
respons
one
might
question
valu
genet
marker
age
ifnfre
daa
treatment
high
cure
rate
note
ifnl
locu
snp
also
predict
daa
treatment
outcom
moreov
influenc
daa
respons
kinet
genet
marker
might
therefor
allow
predict
treatment
durat
consequ
reduc
cost
exposur
time
daa
human
polymorph
ifnl
locu
respons
improv
respons
ifnalpharbv
treatment
also
associ
better
spontan
clearanc
hcv
allel
frequenc
snp
differ
individu
european
african
ancestri
favor
c
variant
predomin
former
popul
find
correl
better
clearanc
hcv
european
ancestri
individu
snp
similarli
predict
hcv
clearanc
rate
howev
better
predictor
snp
africanamerican
predict
valu
snp
similar
europeanamerican
caus
differ
degre
linkag
disequilibrium
snp
two
popul
third
snp
strong
predict
valu
outcom
hcv
infect
also
show
higher
frequenc
protect
allel
individu
european
asian
ancestri
compar
individu
african
ancestri
summari
clear
link
ifnl
gene
snp
hcv
treatment
outcom
well
spontan
clearanc
notabl
except
snp
result
express
mechan
caus
associ
remain
elus
associ
snp
may
true
causal
variant
nonetheless
predict
valu
ifnl
snp
extend
beyond
hepat
c
genet
associ
nonalcohol
fatti
liver
diseas
allergi
infect
cytomegaloviru
human
tlymphotrop
viru
hepat
b
viru
hiv
herp
simplex
viru
suggest
review
discoveri
ifnl
polymorph
context
hcv
infect
may
therefor
importantli
contribut
understand
hepat
extrahepat
diseas
rise
daa
target
hcv
ifnl
consid
attract
altern
ifnalpharbv
treatment
sever
reason
antivir
profil
ifnl
resembl
one
ifnalpha
interferon
signal
via
hold
true
primari
human
hepatocyt
well
hepatoma
cell
line
howev
kinet
magnitud
isg
induct
differ
ifnalpha
ifnl
anoth
differ
two
ifn
type
tissu
specif
caus
diverg
express
pattern
receptor
contrast
ifnl
receptor
complex
show
restrict
tissu
express
ifnalpha
receptor
express
ubiquit
thu
compar
ifnl
ifnalpha
act
system
caus
advers
effect
often
limit
treatment
option
complianc
overlap
respons
ifnalpha
ifnl
signal
one
hand
tissu
specif
ifnlr
hand
made
ifnl
promis
replac
ifnalpha
ifnl
would
yield
therapi
outcom
fewer
side
effect
inde
clinic
studi
reveal
improv
safeti
toler
profil
compar
pegifnalpha
use
combin
rbv
daa
daclatasvir
base
treatment
show
less
advers
event
also
lead
higher
sustain
virolog
respons
treatment
pegifnalpha
base
regim
week
treatment
hcv
rna
detect
blood
patient
group
compar
patient
group
differ
clinic
studi
given
togeth
rbv
telaprevir
noninferior
regard
safeti
toler
efficaci
observ
highest
activ
among
ifnl
type
therefor
might
suitabl
therapeut
agent
nevertheless
evalu
clinic
trial
far
probabl
due
fact
recombin
difficult
produc
recent
analog
allow
high
yield
product
compar
abil
inhibit
hcv
replic
cell
design
howev
licens
effect
daa
pave
way
ifnfre
therapi
chc
becom
standard
care
nowaday
thu
like
ifnl
need
therapeut
agent
hepat
c
futur
develop
hepat
c
drug
fortun
unpreced
success
stori
still
lack
specif
drug
hepatotrop
virus
instanc
hepat
e
viru
sensit
ifnl
vitro
model
current
treatment
option
hepat
e
limit
consequ
mechanist
insight
interplay
ifnl
hcv
might
spur
import
futur
work
role
possibl
therapeut
applic
ifnl
infect
virus
infect
ifnlr
express
tissu
particular
liver
lung
